Christopher K. Murray is VP at Blueprint Medicines Corp (BPMC). They have made 7 open-market trades across 1 company since 2020, most recently 2024-03-07.
CIK 0001718648
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BPMC | 33,853 | $4.4M |
Shares reported on the most recent Form 4, priced at the 2024-03-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPMC | SELL | 2024-03-07 | 2024-03-11 | $90.69 | $457K | +1.0% | +1.5% | +16.7% |
| BPMC | SELL · 10b5-1 | 2024-03-04 | 2024-03-06 | $93.65 | $116K | -3.9% | +1.4% | +12.7% |
| BPMC | SELL · 10b5-1 | 2024-02-28 | 2024-03-01 | $100.00 | $500K | -4.9% | +1.2% | +11.7% |
| BPMC | SELL | 2023-12-07 | 2023-12-11 | $75.00 | $375K | +6.1% | +2.7% | +10.5% |
| BPMC | SELL · 10b5-1 | 2023-12-04 | 2023-12-06 | $71.43 | $43K | +20.1% | +13.8% | +22.9% |
| BPMC | SELL · 10b5-1 | 2023-10-26 | 2023-10-30 | $56.40 | $34K | +5.9% | +26.7% | +57.3% |
| BPMC | SELL | 2023-03-06 | 2023-03-08 | $45.69 | $169K | +3.2% | -3.4% | +32.1% |
| BPMC | SELL | 2022-08-04 | 2022-08-08 | $62.72 | $314K | -8.1% | +8.8% | -38.7% |
| BPMC | SELL | 2022-03-03 | 2022-03-08 | $59.49 | $157K | +17.5% | +23.4% | +4.6% |
| BPMC | SELL | 2021-03-04 | 2021-03-05 | $86.69 | $203K | +10.7% | +4.9% | -9.4% |
| BPMC | SELL | 2020-03-09 | 2020-03-11 | $51.94 | $21K | +6.0% | +32.0% | +51.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.